{"id":"W3178904653","doi":"10.1002/hon.2898","title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"Novartis Pharma; Celgene","keywords":"Ruxolitinib; International Prognostic Scoring System; Medicine; Myelofibrosis; Internal medicine; Adverse effect; Anemia; Clinical endpoint; Janus kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Bone marrow; Janus kinase; Myelodysplastic syndromes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001642833,0.0004026,0.0008321179,0.0002764893,0.0001891025,0.0005080999,0.0002806617,0.0003721635,0.000903019],"category_scores_gemma":[0.001246033,0.0001806133,0.0009040474,0.0002033975,0.000243046,0.0004629739,0.00031286,0.0008428776,0.0001565442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004118206,"about_ca_system_score_gemma":0.0004748721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003636008,"about_ca_topic_score_gemma":0.0009261571,"domain_scores_codex":[0.9995377,0.0001965555,0.00004021479,0.00006386335,0.00008152629,0.00008011818],"domain_scores_gemma":[0.9991358,0.0002444846,0.0002269049,0.0000698108,0.00005591904,0.0002671249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5352927,0.007252531,0.3592971,0.0002517209,0.002323848,0.0002746584,0.0001745868,0.002044097,0.01295925,0.0002415649,0.001744715,0.07814335],"study_design_scores_gemma":[0.09511513,0.1878905,0.7015341,0.00004610541,0.00166169,0.0007788008,0.0001284362,0.006509299,0.003813699,0.0004771149,0.001987432,0.00005770826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991571,0.0003117571,0.00007018103,0.00003171333,0.000006508421,0.0000467231,0.0001302606,0.00000485032,0.0002407948],"genre_scores_gemma":[0.9987503,0.0001052214,0.0001012074,0.0000851626,0.00003163473,0.00006369467,0.0006958792,0.000001753722,0.0001650279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001642833,"threshold_uncertainty_score":0.008688271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02074939354465334,"score_gpt":0.3252005367022574,"score_spread":0.3044511431576041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}